132 related articles for article (PubMed ID: 18539263)
1. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
[TBL] [Abstract][Full Text] [Related]
2. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract][Full Text] [Related]
4. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5.
Sun XD; Shi XJ; Sun XO; Luo YG; Wu XJ; Yao CF; Yu HY; Li DW; Liu M; Zhou J
Acta Pharmacol Sin; 2011 Dec; 32(12):1543-8. PubMed ID: 21986572
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
6. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
7. Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5.
Rello-Varona S; Vitale I; Kepp O; Senovilla L; Jemaá M; Métivier D; Castedo M; Kroemer G
Cell Cycle; 2009 Apr; 8(7):1030-5. PubMed ID: 19270519
[TBL] [Abstract][Full Text] [Related]
8. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
9. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Zhang Y; Xu W
Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
[TBL] [Abstract][Full Text] [Related]
10. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel EG5 inhibitors.
Sarli V; Huemmer S; Sunder-Plassmann N; Mayer TU; Giannis A
Chembiochem; 2005 Nov; 6(11):2005-13. PubMed ID: 16216042
[TBL] [Abstract][Full Text] [Related]
12. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
13. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
14. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.
Ding S; Nishizawa K; Kobayashi T; Oishi S; Lv J; Fujii N; Ogawa O; Nishiyama H
J Urol; 2010 Sep; 184(3):1175-81. PubMed ID: 20663523
[TBL] [Abstract][Full Text] [Related]
15. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
16. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
[TBL] [Abstract][Full Text] [Related]
17. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
18. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
19. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Purcell JW; Davis J; Reddy M; Martin S; Samayoa K; Vo H; Thomsen K; Bean P; Kuo WL; Ziyad S; Billig J; Feiler HS; Gray JW; Wood KW; Cases S
Clin Cancer Res; 2010 Jan; 16(2):566-76. PubMed ID: 20068098
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
